瑞银发表报告指，药明康德中期业绩符合预期，当中收入按年升20.6%，归属股东净利润升95.5%，主要来自药明合联的资产处置收益。经调整非国际财务报告准则净利润为按年增长44.4%。经调整非国际财务报告准则毛利率提升4.7个百分点至44.5%。截至上半年末，公司持续经营业务的未完成订单金额达567亿元，按年增长37.2%，保持强劲。 药明康德将今年全年收入指引由415亿至430亿元，上调至425至435亿元；持续经营业务收入增长指引由10%至15%，上调至13%至17%。考虑到公司一贯保守的指引风格，该行预计实际表现将好超出指引。该行又对其首次宣派中期股息10亿元持积极态度，现予目标价104.6港元及“买入”评级。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.